
|Videos|February 16, 2016
Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for Trials
Author(s)Peter Beitsch, MD
Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Advertisement
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses large studies and their tendencies to not group patients by subtypes. Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5










































